{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:06:59Z","timestamp":1789225619965,"version":"build-2803163510"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Survival of extremely preterm infants has improved owing to advances in perinatal and neonatal care. However, bronchopulmonary dysplasia (BPD) has remained unabated, and research into preventive measures for the broader spectrum of prematurity-associated lung disease (PLD) has met with limited success. We summarize emerging therapeutic strategies with the potential to favorably influence the lifelong trajectory of lung health of preterm infants, especially the most immature. This narrative review examines recent preclinical and clinical studies on therapies for BPD prevention, focusing on mechanism-based interventions, biologic strategies, and innovative translational tools. Preclinical evidence converges on actionable targets in alveolarization, inflammatory pathways, redox and mitochondrial homeostasis, vascular and matrix remodeling. Novel molecules and drug-repurposing strategies are being tested in animal models, while patient-derived platforms may enable personalized therapeutic approaches. Mechanism-based approaches are progressing through Phase 1\u20132 clinical trials; pending efficacy analyses, insulin-like growth factor-1 replacement may become the first pharmacological therapy specifically approved to reduce or attenuate BPD. In parallel, cell-based therapies and extracellular vesicle strategies offer a complementary paradigm, acting through pleiotropic biological reprogramming of the injured lung. Ethical-regulatory complexity and the challenges of standardizing and scaling cell-based and cell-free therapies may limit clinical translation.<\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusion<\/jats:italic>\n                    : A growing repertoire of therapies for BPD holds promise for modifying early respiratory illness and the long-term burden of PLD. Realizing this potential will benefit from both mechanism-informed combinatorial approaches and pleiotropic strategies, supported by patient-derived translational tools and adequately powered efficacy evaluations. Equally essential are tailored neonatal-first regulatory pathways linking the continuum of BPD to the later respiratory morbidity of PLD, a life-course condition with significant public health relevance beyond the neonatal period.\n                    <jats:table-wrap>\n                      <jats:table>\n                        <jats:tbody>\n                          <jats:tr>\n                            <jats:td align=\"left\" colspan=\"2\">\n                              <jats:bold>What is Known:<\/jats:bold>\n                              \u2022\n                              <jats:italic>Bronchopulmonary dysplasia (BPD) is the current clinical and regulatory endpoint for neonatal pulmonary therapies<\/jats:italic>\n                              .\u2022\n                              <jats:italic>BPD definitions capture the most severe manifestations of prematurity-associated lung disease (PLD), a broader continuum of respiratory morbidity reaching into adulthood; attenuating BPD may improve the whole spectrum of PLD<\/jats:italic>\n                              .\n                            <\/jats:td>\n                          <\/jats:tr>\n                          <jats:tr>\n                            <jats:td align=\"left\" colspan=\"2\">\n                              <jats:bold>What is New:<\/jats:bold>\n                              \u2022\n                              <jats:italic>Therapies targeting alveolar, inflammatory, oxidative, vascular, and remodeling pathways are in clinical development; pending late-stage trials, IGF-1 replacement may become the first disease-modifying therapy to reduce BPD<\/jats:italic>\n                              .\u2022\n                              <jats:italic>Novel targets, experimental platforms, and repurposed drugs hold promise for precision therapies in preterm infants<\/jats:italic>\n                              .\n                            <\/jats:td>\n                          <\/jats:tr>\n                        <\/jats:tbody>\n                      <\/jats:table>\n                    <\/jats:table-wrap>\n                  <\/jats:p>","DOI":"10.1007\/s00431-026-07366-8","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:07:31Z","timestamp":1788584851000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bronchopulmonary dysplasia and prematurity-associated lung disease: emerging therapies to improve lifelong respiratory outcomes"],"prefix":"10.1007","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4919-569X","authenticated-orcid":false,"given":"Lorenzo","family":"Zanetto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7700-3056","authenticated-orcid":false,"given":"Luca","family":"Bonadies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Salvadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Priante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Nardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5990-7235","authenticated-orcid":false,"given":"Victoria","family":"Niklas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3846-4834","authenticated-orcid":false,"given":"Daniele","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1829-3652","authenticated-orcid":false,"given":"Eugenio","family":"Baraldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,5]]},"reference":[{"key":"7366_CR1","volume-title":"Born too soon: decade of action on preterm birth","author":"World Health Organization","year":"2023","unstructured":"World Health Organization, UNFPA, UNICEF, PMNCH (2023) Born too soon: decade of action on preterm birth. World Health Organization, Geneva"},{"key":"7366_CR2","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/thoraxjnl-2012-203079","volume":"68","author":"SJ Kotecha","year":"2013","unstructured":"Kotecha SJ, Edwards MO, Watkins WJ et al (2013) Effect of preterm birth on later FEV1: a systematic review and meta-analysis. Thorax 68:760\u2013766. https:\/\/doi.org\/10.1136\/thoraxjnl-2012-203079","journal-title":"Thorax"},{"key":"7366_CR3","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00046-2023","volume":"9","author":"JTD Gibbons","year":"2023","unstructured":"Gibbons JTD, Course CW, Evans EE et al (2023) Increasing airway obstruction through life following bronchopulmonary dysplasia: a meta-analysis. ERJ Open Res 9:00046-2023. https:\/\/doi.org\/10.1183\/23120541.00046-2023","journal-title":"ERJ Open Res"},{"key":"7366_CR4","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S2213-2600(21)00508-7","volume":"10","author":"DS Bui","year":"2022","unstructured":"Bui DS, Perret JL, Walters EH et al (2022) Association between very to moderate preterm births, lung function deficits, and COPD at age 53 years: analysis of a prospective cohort study. Lancet Respir Med 10:478\u2013484. https:\/\/doi.org\/10.1016\/S2213-2600(21)00508-7","journal-title":"Lancet Respir Med"},{"key":"7366_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S2213-2600(23)00272-2","volume":"12","author":"SJ Simpson","year":"2024","unstructured":"Simpson SJ, Du Berry C, Evans DJ et al (2024) Unravelling the respiratory health path across the lifespan for survivors of preterm birth. Lancet Respir Med 12:167\u2013180. https:\/\/doi.org\/10.1016\/S2213-2600(23)00272-2","journal-title":"Lancet Respir Med"},{"key":"7366_CR6","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1164\/rccm.201812-2348OC","volume":"200","author":"EA Jensen","year":"2019","unstructured":"Jensen EA, Dysart K, Gantz MG et al (2019) The diagnosis of bronchopulmonary dysplasia in very preterm infants. An evidence-based approach. Am J Respir Crit Care Med 200:751\u2013759. https:\/\/doi.org\/10.1164\/rccm.201812-2348OC","journal-title":"Am J Respir Crit Care Med"},{"key":"7366_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jpeds.2021.03.063","volume":"234","author":"AH Jobe","year":"2021","unstructured":"Jobe AH, Bancalari E (2021) An all-inclusive perspective on bronchopulmonary dysplasia. J Pediatr 234:257\u2013259. https:\/\/doi.org\/10.1016\/j.jpeds.2021.03.063","journal-title":"J Pediatr"},{"key":"7366_CR8","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1056\/NEJM196702162760701","volume":"276","author":"WHJ Northway","year":"1967","unstructured":"Northway WHJ, Rosan RC, Porter DY (1967) Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 276:357\u2013368. https:\/\/doi.org\/10.1056\/NEJM196702162760701","journal-title":"N Engl J Med"},{"key":"7366_CR9","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMra067279","volume":"357","author":"E Baraldi","year":"2007","unstructured":"Baraldi E, Filippone M (2007) Chronic lung disease after premature birth. N Engl J Med 357:1946\u20131955. https:\/\/doi.org\/10.1056\/NEJMra067279","journal-title":"N Engl J Med"},{"key":"7366_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41572-019-0127-7","volume":"5","author":"B Th\u00e9baud","year":"2019","unstructured":"Th\u00e9baud B, Goss KN, Laughon M et al (2019) Bronchopulmonary dysplasia Nat Rev Dis Primers 5:78. https:\/\/doi.org\/10.1038\/s41572-019-0127-7","journal-title":"Bronchopulmonary dysplasia Nat Rev Dis Primers"},{"key":"7366_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101597","volume":"52","author":"C Du Berry","year":"2022","unstructured":"Du Berry C, Nesci C, Cheong JLY et al (2022) Long-term expiratory airflow of infants born moderate-late preterm: a systematic review and meta-analysis. eClinicalMedicine 52:101597. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101597","journal-title":"eClinicalMedicine"},{"key":"7366_CR12","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1164\/rccm.202505-1157VP","volume":"211","author":"L Zanetto","year":"2025","unstructured":"Zanetto L, Bonadies L, Pertoldi C et al (2025) Targeting treatable traits across the lifespan in preterm-born individuals with chronic lung disease of prematurity. Am J Respir Crit Care Med 211:1996\u20131998. https:\/\/doi.org\/10.1164\/rccm.202505-1157VP","journal-title":"Am J Respir Crit Care Med"},{"key":"7366_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S2213-2600(25)00372-8","volume":"14","author":"CW Course","year":"2026","unstructured":"Course CW, Bush A, Kotecha S (2026) Looking beyond bronchopulmonary dysplasia: prematurity-associated lung disease and its phenotypes. Lancet Respir Med 14:60\u201371. https:\/\/doi.org\/10.1016\/S2213-2600(25)00372-8","journal-title":"Lancet Respir Med"},{"key":"7366_CR14","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0304-2025","volume":"35","author":"L Bonadies","year":"2026","unstructured":"Bonadies L, Zanetto L, Ferraro VA et al (2026) Bronchopulmonary dysplasia and extremely preterm birth: time for a broader perspective on long-term outcomes. Eur Respir Rev 35:250304. https:\/\/doi.org\/10.1183\/16000617.0304-2025","journal-title":"Eur Respir Rev"},{"key":"7366_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00431-025-06713-5","volume":"185","author":"A Jenkinson","year":"2026","unstructured":"Jenkinson A, Dassios T (2026) Follow-up of neonatal chronic respiratory disease: an update based on the current evidence. Eur J Pediatr 185:61. https:\/\/doi.org\/10.1007\/s00431-025-06713-5","journal-title":"Eur J Pediatr"},{"key":"7366_CR16","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/jama.2024.17380","volume":"332","author":"BJ Manley","year":"2024","unstructured":"Manley BJ, Kamlin COF, Donath SM et al (2024) Intratracheal budesonide mixed with surfactant for extremely preterm infants: the PLUSS randomized clinical trial. JAMA 332:1889. https:\/\/doi.org\/10.1001\/jama.2024.17380","journal-title":"JAMA"},{"key":"7366_CR17","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJM199311253292201","volume":"329","author":"MC Allen","year":"1993","unstructured":"Allen MC, Donohue PK, Dusman AE (1993) The limit of viability \u2013 neonatal outcome of infants born at 22 to 25 weeks\u2019 gestation. N Engl J Med 329:1597\u20131601. https:\/\/doi.org\/10.1056\/NEJM199311253292201","journal-title":"N Engl J Med"},{"key":"7366_CR18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1164\/rccm.201401-0168CP","volume":"190","author":"MCJ Kneyber","year":"2014","unstructured":"Kneyber MCJ, Zhang H, Slutsky AS (2014) Ventilator-induced lung injury. Similarity and differences between children and adults. Am J Respir Crit Care Med 190:258\u2013265. https:\/\/doi.org\/10.1164\/rccm.201401-0168CP","journal-title":"Am J Respir Crit Care Med"},{"key":"7366_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jpeds.2017.08.041","volume":"190","author":"CM Alvira","year":"2017","unstructured":"Alvira CM, Morty RE (2017) Can we understand the pathobiology of bronchopulmonary dysplasia? J Pediatr 190:27\u201337. https:\/\/doi.org\/10.1016\/j.jpeds.2017.08.041","journal-title":"J Pediatr"},{"key":"7366_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9051539","volume":"9","author":"L Bonadies","year":"2020","unstructured":"Bonadies L, Zaramella P, Porzionato A et al (2020) Present and future of bronchopulmonary dysplasia. JCM 9:1539. https:\/\/doi.org\/10.3390\/jcm9051539","journal-title":"JCM"},{"key":"7366_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2026.103408","volume":"57","author":"D Wang","year":"2026","unstructured":"Wang D, Wang S, Wang H, Zhang X (2026) A randomized controlled trial of probiotic intervention for reducing the risk of bronchopulmonary dysplasia in preterm infants. Arch Med Res 57:103408. https:\/\/doi.org\/10.1016\/j.arcmed.2026.103408","journal-title":"Arch Med Res"},{"key":"7366_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/nu9111197","volume":"9","author":"E Villamor-Mart\u00ednez","year":"2017","unstructured":"Villamor-Mart\u00ednez E, Pierro M, Cavallaro G et al (2017) Probiotic supplementation in preterm infants does not affect the risk of bronchopulmonary dysplasia: a meta-analysis of randomized controlled trials. Nutrients 9:1197. https:\/\/doi.org\/10.3390\/nu9111197","journal-title":"Nutrients"},{"key":"7366_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96489-z","volume":"11","author":"Y Qu","year":"2021","unstructured":"Qu Y, Guo S, Liu Y et al (2021) Association between probiotics and bronchopulmonary dysplasia in preterm infants. Sci Rep 11:17060. https:\/\/doi.org\/10.1038\/s41598-021-96489-z","journal-title":"Sci Rep"},{"key":"7366_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/mmr.2025.13678","volume":"32","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Ding R-D (2025) Role of the gut\u2011lung axis in bronchopulmonary dysplasia: physiological basis, pathogenesis and immunological modulation (review). Mol Med Rep 32:1\u201312. https:\/\/doi.org\/10.3892\/mmr.2025.13678","journal-title":"Mol Med Rep"},{"key":"7366_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106758","volume":"191","author":"KR Keever","year":"2023","unstructured":"Keever KR, Yakubenko VP, Hoover DB (2023) Neuroimmune nexus in the pathophysiology and therapy of inflammatory disorders: role of \u03b17 nicotinic acetylcholine receptors. Pharmacol Res 191:106758. https:\/\/doi.org\/10.1016\/j.phrs.2023.106758","journal-title":"Pharmacol Res"},{"key":"7366_CR26","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1136\/thorax-2025-223090","volume":"81","author":"L Bonadies","year":"2026","unstructured":"Bonadies L, Calgaro S, Stocchero M et al (2026) Early prediction of bronchopulmonary dysplasia by urinary metabolomics: a case\u2013control study. Thorax 81:276\u2013281. https:\/\/doi.org\/10.1136\/thorax-2025-223090","journal-title":"Thorax"},{"key":"7366_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.71644","volume":"61","author":"L Strauch","year":"2026","unstructured":"Strauch L, Lang P, Cheema Z et al (2026) Urine metabolomics to predict bronchopulmonary dysplasia: a single-center prospective study. Pediatr Pulmonol 61:e71644. https:\/\/doi.org\/10.1002\/ppul.71644","journal-title":"Pediatr Pulmonol"},{"key":"7366_CR28","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1203\/PDR.0b013e3181f90278","volume":"68","author":"A Vadivel","year":"2010","unstructured":"Vadivel A, Aschner JL, Rey-Parra GJ et al (2010) L-citrulline attenuates arrested alveolar growth and pulmonary hypertension in oxygen-induced lung injury in newborn rats. Pediatr Res 68:519\u2013525. https:\/\/doi.org\/10.1203\/PDR.0b013e3181f90278","journal-title":"Pediatr Res"},{"key":"7366_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.prrv.2023.05.001","volume":"48","author":"BW Kramer","year":"2023","unstructured":"Kramer BW, Abman S, Daly M et al (2023) Insulin-like growth factor-1 replacement therapy after extremely premature birth: an opportunity to optimize lifelong lung health by preserving the natural sequence of lung development. Paediatr Respir Rev 48:24\u201329. https:\/\/doi.org\/10.1016\/j.prrv.2023.05.001","journal-title":"Paediatr Respir Rev"},{"key":"7366_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjpo-2025-004196","volume":"10","author":"E Baraldi","year":"2026","unstructured":"Baraldi E, De Luca D, Bonadies L et al (2026) Randomised phase 2b trial of rhIGF-1\/rhIGFBP-3 (OHB-607) for bronchopulmonary dysplasia prevention in preterm neonates: study protocol. BMJ Paediatr Open 10:e004196. https:\/\/doi.org\/10.1136\/bmjpo-2025-004196","journal-title":"BMJ Paediatr Open"},{"key":"7366_CR31","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2022.11114","volume":"23","author":"S Zhang","year":"2022","unstructured":"Zhang S, Luan X, Li H, Jin Z (2022) Insulin-like growth factor-1: a potential target for bronchopulmonary dysplasia treatment (Review). Exp Ther Med 23:191. https:\/\/doi.org\/10.3892\/etm.2022.11114","journal-title":"Exp Ther Med"},{"key":"7366_CR32","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1164\/rccm.202002-0287ED","volume":"201","author":"EJ Plosa","year":"2020","unstructured":"Plosa EJ, Benjamin JT (2020) rhIGF-1 therapy: a silver bullet for bronchopulmonary dysplasia prevention? Am J Respir Crit Care Med 201:1032\u20131033. https:\/\/doi.org\/10.1164\/rccm.202002-0287ED","journal-title":"Am J Respir Crit Care Med"},{"key":"7366_CR33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00431-025-06016-9","volume":"184","author":"C Ramos-Navarro","year":"2025","unstructured":"Ramos-Navarro C, Gregorio-Hern\u00e1ndez R, P\u00e9rez-P\u00e9rez A et al (2025) Impact of placental pathology on the risk of bronchopulmonary dysplasia in preterm infants: the role of gestational age and sex. Eur J Pediatr 184:211. https:\/\/doi.org\/10.1007\/s00431-025-06016-9","journal-title":"Eur J Pediatr"},{"key":"7366_CR34","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/S2213-2600(24)00079-1","volume":"12","author":"J Lowe","year":"2024","unstructured":"Lowe J, Gillespie D, Aboklaish A et al (2024) Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Respir Med 12:608\u2013618. https:\/\/doi.org\/10.1016\/S2213-2600(24)00079-1","journal-title":"Lancet Respir Med"},{"key":"7366_CR35","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1093\/ajrccm\/aamaf105","volume":"212","author":"KH Albertine","year":"2026","unstructured":"Albertine KH, Rebentisch A, Dawson E et al (2026) Recombinant human insulin-like growth factor 1 complex preserves lung development in mechanically ventilated preterm lambs. Am J Respir Crit Care Med 212:778\u2013791. https:\/\/doi.org\/10.1093\/ajrccm\/aamaf105","journal-title":"Am J Respir Crit Care Med"},{"key":"7366_CR36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jpeds.2018.10.033","volume":"206","author":"D Ley","year":"2019","unstructured":"Ley D, Hallberg B, Hansen-Pupp I et al (2019) rhIGF-1\/rhIGFBP-3 in preterm infants: a phase 2 randomized controlled trial. J Pediatr 206:56-65.e8. https:\/\/doi.org\/10.1016\/j.jpeds.2018.10.033","journal-title":"J Pediatr"},{"key":"7366_CR37","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1002\/sctm.17-0126","volume":"6","author":"S Augustine","year":"2017","unstructured":"Augustine S, Avey MT, Harrison B et al (2017) Mesenchymal stromal cell therapy in bronchopulmonary dysplasia: systematic review and meta-analysis of preclinical studies. Stem Cells Transl Med 6:2079\u20132093. https:\/\/doi.org\/10.1002\/sctm.17-0126","journal-title":"Stem Cells Transl Med"},{"key":"7366_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41536-019-0083-6","volume":"4","author":"MF Pittenger","year":"2019","unstructured":"Pittenger MF, Discher DE, P\u00e9ault BM et al (2019) Mesenchymal stem cell perspective: cell biology to clinical progress. npj Regen Med 4:22. https:\/\/doi.org\/10.1038\/s41536-019-0083-6","journal-title":"npj Regen Med"},{"key":"7366_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/cph4.70038","volume":"15","author":"M Deguise","year":"2025","unstructured":"Deguise M, Th\u00e9baud B (2025) The role of mesenchymal stromal cells in the treatment of bronchopulmonary dysplasia: a multi-prong approach for a heterogeneous disease. Compr Physiol 15:e70038. https:\/\/doi.org\/10.1002\/cph4.70038","journal-title":"Compr Physiol"},{"key":"7366_CR40","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1161\/STROKEAHA.112.679092","volume":"44","author":"SY Ahn","year":"2013","unstructured":"Ahn SY, Chang YS, Sung DK et al (2013) Mesenchymal stem cells prevent hydrocephalus after severe intraventricular hemorrhage. Stroke 44:497\u2013504. https:\/\/doi.org\/10.1161\/STROKEAHA.112.679092","journal-title":"Stroke"},{"key":"7366_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.semperi.2024.151929","volume":"48","author":"A Mintoft","year":"2024","unstructured":"Mintoft A, Vallatos A, Robertson NJ (2024) Mesenchymal stromal cell therapy for hypoxic ischemic encephalopathy: future directions for combination therapy with hypothermia and\/or melatonin. Semin Perinatol 48:151929. https:\/\/doi.org\/10.1016\/j.semperi.2024.151929","journal-title":"Semin Perinatol"},{"key":"7366_CR42","doi-asserted-by":"publisher","DOI":"10.1093\/stcltm\/szae102","volume":"14","author":"C Maltais-Bilodeau","year":"2025","unstructured":"Maltais-Bilodeau C, Henckel E, Deguise M-O et al (2025) Cell-based therapies in preclinical models of necrotizing enterocolitis: a systematic review and meta-analysis. Stem Cells Transl Med 14:szae102. https:\/\/doi.org\/10.1093\/stcltm\/szae102","journal-title":"Stem Cells Transl Med"},{"key":"7366_CR43","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1089\/scd.2016.0329","volume":"26","author":"Y Zhu","year":"2017","unstructured":"Zhu Y, Xu L, Collins JJP et al (2017) Human umbilical cord mesenchymal stromal cells improve survival and bacterial clearance in neonatal sepsis in rats. Stem Cells Dev 26:1054\u20131064. https:\/\/doi.org\/10.1089\/scd.2016.0329","journal-title":"Stem Cells Dev"},{"key":"7366_CR44","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1164\/rccm.202310-1975OC","volume":"210","author":"C Cyr-Depauw","year":"2024","unstructured":"Cyr-Depauw C, Cook DP, Mi\u017eik I et al (2024) Single-cell RNA sequencing reveals repair features of human umbilical cord mesenchymal stromal cells. Am J Respir Crit Care Med 210:814\u2013827. https:\/\/doi.org\/10.1164\/rccm.202310-1975OC","journal-title":"Am J Respir Crit Care Med"},{"key":"7366_CR45","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1164\/rccm.202403-0569OC","volume":"211","author":"C Cyr-Depauw","year":"2025","unstructured":"Cyr-Depauw C, Mi\u017eik I, Cook DP et al (2025) Single-cell RNA sequencing to guide autologous preterm cord mesenchymal stromal cell therapy. Am J Respir Crit Care Med 211:391\u2013406. https:\/\/doi.org\/10.1164\/rccm.202403-0569OC","journal-title":"Am J Respir Crit Care Med"},{"key":"7366_CR46","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.jpeds.2013.12.011","volume":"164","author":"YS Chang","year":"2014","unstructured":"Chang YS, Ahn SY, Yoo HS et al (2014) Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. J Pediatr 164:966-972.e6. https:\/\/doi.org\/10.1016\/j.jpeds.2013.12.011","journal-title":"J Pediatr"},{"key":"7366_CR47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jpeds.2017.02.061","volume":"185","author":"SY Ahn","year":"2017","unstructured":"Ahn SY, Chang YS, Kim JH et al (2017) Two-year follow-up outcomes of premature infants enrolled in the phase I trial of mesenchymal stem cells transplantation for bronchopulmonary dysplasia. J Pediatr 185:49-54.e2. https:\/\/doi.org\/10.1016\/j.jpeds.2017.02.061","journal-title":"J Pediatr"},{"key":"7366_CR48","doi-asserted-by":"publisher","unstructured":"Pierro M, Th\u00e9baud B, Soll R (2017) Mesenchymal stem cells for the prevention and treatment of bronchopulmonary dysplasia in preterm infants. Cochrane Database of Systematic Reviews 2017:. https:\/\/doi.org\/10.1002\/14651858.CD011932.pub2","DOI":"10.1002\/14651858.CD011932.pub2"},{"key":"7366_CR49","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1136\/thorax-2022-219622","volume":"78","author":"SY Ahn","year":"2023","unstructured":"Ahn SY, Chang YS, Lee MH et al (2023) Five-year follow-up of phase II trial of stromal cells for bronchopulmonary dysplasia. Thorax 78:1105\u20131110","journal-title":"Thorax"},{"key":"7366_CR50","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I et al (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315\u2013317. https:\/\/doi.org\/10.1080\/14653240600855905","journal-title":"Cytotherapy"},{"key":"7366_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12404","volume":"13","author":"JA Welsh","year":"2024","unstructured":"Welsh JA, Goberdhan DCI, O\u2019Driscoll L et al (2024) Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J of Extracellular Vesicle 13:e12404. https:\/\/doi.org\/10.1002\/jev2.12404","journal-title":"J of Extracellular Vesicle"},{"key":"7366_CR52","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/s41390-024-03471-2","volume":"97","author":"H Saneh","year":"2025","unstructured":"Saneh H, Wanczyk H, Walker J, Finck C (2025) Stem cell-derived extracellular vesicles: a potential intervention for bronchopulmonary dysplasia. Pediatr Res 97:497\u2013509. https:\/\/doi.org\/10.1038\/s41390-024-03471-2","journal-title":"Pediatr Res"},{"key":"7366_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/cells11071176","volume":"11","author":"F Lesage","year":"2022","unstructured":"Lesage F, Th\u00e9baud B (2022) Mesenchymal stromal cell-derived extracellular vesicles for neonatal lung disease: tiny particles, major promise, rigorous requirements for clinical translation. Cells 11:1176. https:\/\/doi.org\/10.3390\/cells11071176","journal-title":"Cells"},{"key":"7366_CR54","doi-asserted-by":"publisher","first-page":"L517","DOI":"10.1152\/ajplung.00244.2023","volume":"326","author":"MA Ransom","year":"2024","unstructured":"Ransom MA, Blatt AM, Pua HH, Sucre JMS (2024) The emerging role of extracellular vesicles in bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 326:L517\u2013L523. https:\/\/doi.org\/10.1152\/ajplung.00244.2023","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"7366_CR55","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1164\/rccm.201705-0925OC","volume":"197","author":"GR Willis","year":"2018","unstructured":"Willis GR, Fernandez-Gonzalez A, Anastas J et al (2018) Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through macrophage immunomodulation. Am J Respir Crit Care Med 197:104\u2013116. https:\/\/doi.org\/10.1164\/rccm.201705-0925OC","journal-title":"Am J Respir Crit Care Med"},{"key":"7366_CR56","doi-asserted-by":"publisher","DOI":"10.1080\/20013078.2020.1790874","volume":"9","author":"GR Willis","year":"2020","unstructured":"Willis GR, Fernandez\u2010Gonzalez A, Reis M et al (2020) Mesenchymal stromal cell\u2010derived small extracellular vesicles restore lung architecture and improve exercise capacity in a model of neonatal hyperoxia\u2010induced lung injury. J of Extracellular Vesicle 9:1790874. https:\/\/doi.org\/10.1080\/20013078.2020.1790874","journal-title":"J of Extracellular Vesicle"},{"key":"7366_CR57","doi-asserted-by":"publisher","first-page":"L6","DOI":"10.1152\/ajplung.00109.2018","volume":"316","author":"A Porzionato","year":"2019","unstructured":"Porzionato A, Zaramella P, Dedja A et al (2019) Intratracheal administration of clinical-grade mesenchymal stem cell-derived extracellular vesicles reduces lung injury in a rat model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 316:L6\u2013L19. https:\/\/doi.org\/10.1152\/ajplung.00109.2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"7366_CR58","doi-asserted-by":"publisher","unstructured":"Porzionato A, Zaramella P, Dedja A et al (2021) Intratracheal administration of mesenchymal stem cell-derived extracellular vesicles reduces lung injuries in a chronic rat model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 320:L688\u2013L704. https:\/\/doi.org\/10.1152\/ajplung.00148.202","DOI":"10.1152\/ajplung.00148.202"},{"key":"7366_CR59","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/stcltm\/szad070","volume":"13","author":"P Bisaccia","year":"2024","unstructured":"Bisaccia P, Magarotto F, D\u2019Agostino S et al (2024) Extracellular vesicles from mesenchymal umbilical cord cells exert protection against oxidative stress and fibrosis in a rat model of bronchopulmonary dysplasia. Stem Cells Transl Med 13:43\u201359. https:\/\/doi.org\/10.1093\/stcltm\/szad070","journal-title":"Stem Cells Transl Med"},{"key":"7366_CR60","doi-asserted-by":"publisher","first-page":"L179","DOI":"10.1152\/ajplung.00329.2021","volume":"322","author":"AN Abele","year":"2022","unstructured":"Abele AN, Taglauer ES, Almeda M et al (2022) Antenatal mesenchymal stromal cell extracellular vesicle treatment preserves lung development in a model of bronchopulmonary dysplasia due to chorioamnionitis. Am J Physiol Lung Cell Mol Physiol 322:L179\u2013L190. https:\/\/doi.org\/10.1152\/ajplung.00329.2021","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"7366_CR61","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1164\/rccm.202012-4520OC","volume":"205","author":"MA Lithopoulos","year":"2022","unstructured":"Lithopoulos MA, Strueby L, O\u2019Reilly M et al (2022) Pulmonary and neurologic effects of mesenchymal stromal cell extracellular vesicles in a multifactorial lung injury model. Am J Respir Crit Care Med 205:1186\u20131201. https:\/\/doi.org\/10.1164\/rccm.202012-4520OC","journal-title":"Am J Respir Crit Care Med"},{"key":"7366_CR62","doi-asserted-by":"publisher","first-page":"L770","DOI":"10.1152\/ajplung.00349.2023","volume":"326","author":"KH Albertine","year":"2024","unstructured":"Albertine KH, Rebentisch A, Dawson E et al (2024) Mesenchymal stromal cell extracellular vesicles improve lung development in mechanically ventilated preterm lambs. Am J Physiol Lung Cell Mol Physiol 326:L770\u2013L785. https:\/\/doi.org\/10.1152\/ajplung.00349.2023","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"7366_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-021-01738-4","volume":"22","author":"R Arroyo","year":"2021","unstructured":"Arroyo R, Kingma PS (2021) Surfactant protein D and bronchopulmonary dysplasia: a new way to approach an old problem. Respir Res 22:141. https:\/\/doi.org\/10.1186\/s12931-021-01738-4","journal-title":"Respir Res"},{"key":"7366_CR64","doi-asserted-by":"publisher","first-page":"L411","DOI":"10.1152\/ajplung.00079.2023","volume":"325","author":"D De Luca","year":"2023","unstructured":"De Luca D, Arroyo R, Foligno S et al (2023) Early life surfactant protein-D levels in bronchoalveolar lavage fluids of extremely preterm neonates. Am J Physiol Lung Cell Mol Physiol 325:L411\u2013L418. https:\/\/doi.org\/10.1152\/ajplung.00079.2023","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"7366_CR65","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1136\/thoraxjnl-2012-202729","volume":"68","author":"S Kotecha","year":"2013","unstructured":"Kotecha S, Davies PL, Clark HW, McGreal EP (2013) Increased prevalence of low oligomeric state surfactant protein D with restricted lectin activity in bronchoalveolar lavage fluid from preterm infants. Thorax 68:460\u2013467. https:\/\/doi.org\/10.1136\/thoraxjnl-2012-202729","journal-title":"Thorax"},{"key":"7366_CR66","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1164\/rccm.202311-2084LE","volume":"209","author":"VG Jain","year":"2024","unstructured":"Jain VG, Parikh NA, Rysavy MA et al (2024) Histological chorioamnionitis increases the risk of bronchopulmonary dysplasia. Am J Respir Crit Care Med 209:1272\u20131275. https:\/\/doi.org\/10.1164\/rccm.202311-2084LE","journal-title":"Am J Respir Crit Care Med"},{"key":"7366_CR67","doi-asserted-by":"publisher","first-page":"L121","DOI":"10.1152\/ajplung.00516.2021","volume":"323","author":"D De Luca","year":"2022","unstructured":"De Luca D, Foligno S, Autilio C et al (2022) Secretory phospholipase A2 expression and activity in preterm clinical chorioamnionitis with fetal involvement. Am J Physiol Lung Cell Mol Physiol 323:L121\u2013L128. https:\/\/doi.org\/10.1152\/ajplung.00516.2021","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"7366_CR68","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1203\/01.PDR.0000054653.89527.F8","volume":"53","author":"MW Beresford","year":"2003","unstructured":"Beresford MW, Shaw NJ (2003) Bronchoalveolar lavage surfactant protein A, B, and D concentrations in preterm infants ventilated for respiratory distress syndrome receiving natural and synthetic surfactants. Pediatr Res 53:663\u2013670. https:\/\/doi.org\/10.1203\/01.PDR.0000054653.89527.F8","journal-title":"Pediatr Res"},{"key":"7366_CR69","doi-asserted-by":"publisher","first-page":"L95","DOI":"10.1152\/ajplung.00462.2019","volume":"319","author":"D De Luca","year":"2020","unstructured":"De Luca D, Shankar-Aguilera S, Autilio C et al (2020) Surfactant-secreted phospholipase A2 interplay and respiratory outcome in preterm neonates. Am J Physiol Lung Cell Mol Physiol 319:L95\u2013L104. https:\/\/doi.org\/10.1152\/ajplung.00462.2019","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"7366_CR70","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.jpeds.2014.05.042","volume":"165","author":"GL Sorensen","year":"2014","unstructured":"Sorensen GL, Dahl M, Tan Q et al (2014) Surfactant protein-D\u2013encoding gene variant polymorphisms are linked to respiratory outcome in premature infants. J Pediatr 165:683\u2013689. https:\/\/doi.org\/10.1016\/j.jpeds.2014.05.042","journal-title":"J Pediatr"},{"key":"7366_CR71","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1080\/14767058.2017.1392506","volume":"32","author":"S Vinod","year":"2019","unstructured":"Vinod S, Gow A, Weinberger B et al (2019) Serum surfactant protein D as a marker for bronchopulmonary dysplasia. J Matern Fetal Neonatal Med 32:815\u2013819. https:\/\/doi.org\/10.1080\/14767058.2017.1392506","journal-title":"J Matern Fetal Neonatal Med"},{"key":"7366_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1022104","volume":"13","author":"EA Green","year":"2022","unstructured":"Green EA, Metz D, Galinsky R et al (2022) Anakinra pilot \u2013 a clinical trial to demonstrate safety, feasibility and pharmacokinetics of interleukin 1 receptor antagonist in preterm infants. Front Immunol 13:1022104. https:\/\/doi.org\/10.3389\/fimmu.2022.1022104","journal-title":"Front Immunol"},{"key":"7366_CR73","doi-asserted-by":"publisher","first-page":"L49","DOI":"10.1152\/ajplung.00060.2019","volume":"317","author":"LC Eldredge","year":"2019","unstructured":"Eldredge LC, Creasy RS, Presnell S et al (2019) Infants with evolving bronchopulmonary dysplasia demonstrate monocyte-specific expression of IL-1 in tracheal aspirates. Am J Physiol Lung Cell Mol Physiol 317:L49\u2013L56. https:\/\/doi.org\/10.1152\/ajplung.00060.2019","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"7366_CR74","doi-asserted-by":"publisher","first-page":"14384","DOI":"10.1073\/pnas.1306859110","volume":"110","author":"MF Nold","year":"2013","unstructured":"Nold MF, Mangan NE, Rudloff I et al (2013) Interleukin-1 receptor antagonist prevents murine bronchopulmonary dysplasia induced by perinatal inflammation and hyperoxia. Proc Natl Acad Sci U S A 110:14384\u201314389. https:\/\/doi.org\/10.1073\/pnas.1306859110","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7366_CR75","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1165\/rcmb.2016-0031OC","volume":"55","author":"SG Royce","year":"2016","unstructured":"Royce SG, Nold MF, Bui C et al (2016) Airway remodeling and hyperreactivity in a model of bronchopulmonary dysplasia and their modulation by IL-1 receptor antagonist. Am J Respir Cell Mol Biol 55:858\u2013868. https:\/\/doi.org\/10.1165\/rcmb.2016-0031OC","journal-title":"Am J Respir Cell Mol Biol"},{"key":"7366_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01480","volume":"10","author":"CB Bui","year":"2019","unstructured":"Bui CB, Kolodziej M, Lamanna E et al (2019) Interleukin-1 receptor antagonist protects newborn mice against pulmonary hypertension. Front Immunol 10:1480. https:\/\/doi.org\/10.3389\/fimmu.2019.01480","journal-title":"Front Immunol"},{"key":"7366_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2026.1806329","volume":"14","author":"DU De Rose","year":"2026","unstructured":"De Rose DU, Cesaroni GM, Campi F et al (2026) Respiratory effects of off label anakinra in critically ill neonates: a 15-patient observational cohort study. Front Pediatr 14:1806329. https:\/\/doi.org\/10.3389\/fped.2026.1806329","journal-title":"Front Pediatr"},{"key":"7366_CR78","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40272-022-00542-x","volume":"25","author":"CD Fike","year":"2023","unstructured":"Fike CD, Avachat C, Birnbaum AK et al (2023) Pharmacokinetics of l-citrulline in neonates at risk of developing bronchopulmonary dysplasia-associated pulmonary hypertension. Pediatr Drugs 25:87\u201396. https:\/\/doi.org\/10.1007\/s40272-022-00542-x","journal-title":"Pediatr Drugs"},{"key":"7366_CR79","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/apa.12707","volume":"103","author":"CD Fike","year":"2014","unstructured":"Fike CD, Summar M, Aschner JL (2014) L-citrulline provides a novel strategy for treating chronic pulmonary hypertension in newborn infants. Acta Paediatr 103:1019\u20131026. https:\/\/doi.org\/10.1111\/apa.12707","journal-title":"Acta Paediatr"},{"key":"7366_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2026.104057","volume":"90","author":"S Sonti","year":"2026","unstructured":"Sonti S, Cantu A, Cantu Guttierez M et al (2026) Patient-derived lung organoids from bronchoalveolar lavage capture epithelial heterogeneity and disease biology in bronchopulmonary dysplasia. Redox Biol 90:104057. https:\/\/doi.org\/10.1016\/j.redox.2026.104057","journal-title":"Redox Biol"},{"key":"7366_CR81","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0255-2024","volume":"34","author":"L Zanetto","year":"2025","unstructured":"Zanetto L, Bonadies L, Moll-Diaz R et al (2025) Lung organoids: a new frontier in neonatology and paediatric respiratory medicine. Eur Respir Rev 34:240255. https:\/\/doi.org\/10.1183\/16000617.0255-2024","journal-title":"Eur Respir Rev"},{"key":"7366_CR82","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1042\/CS20242275","volume":"139","author":"AH Le\u00f3n Silva","year":"2025","unstructured":"Le\u00f3n Silva AH, Tian R, Ballengee S et al (2025) Caspase-1 inhibition mitigates neonatal hyperoxia-induced vascular and cardiopulmonary inflammation in neonatal rats. Clin Sci (Lond) 139:1611\u20131627. https:\/\/doi.org\/10.1042\/CS20242275","journal-title":"Clin Sci (Lond)"},{"key":"7366_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2026.110748","volume":"778","author":"Y Feng","year":"2026","unstructured":"Feng Y, Chen D-Z, Cai H, Zhang Q-Y (2026) Dexmedetomidine attenuates hyperoxia-induced lung injury in BPD mice via regulation of the mitophagy\u2013NLRP3\u2013pyroptosis pathway. Arch Biochem Biophys 778:110748. https:\/\/doi.org\/10.1016\/j.abb.2026.110748","journal-title":"Arch Biochem Biophys"},{"key":"7366_CR84","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1038\/s41390-025-04364-8","volume":"99","author":"J Zhang","year":"2026","unstructured":"Zhang J, Zhou L, Xu H et al (2026) Betaine improves hyperoxic lung injury through downregulating pulmonary macrophage pyroptosis in newborn mice. Pediatr Res 99:1613\u20131620. https:\/\/doi.org\/10.1038\/s41390-025-04364-8","journal-title":"Pediatr Res"},{"key":"7366_CR85","doi-asserted-by":"publisher","first-page":"933","DOI":"10.24976\/Discov.Med.202537196.83","volume":"37","author":"X Yang","year":"2025","unstructured":"Yang X, Luo G, Lou F (2025) Nesfatin-1 suppresses inflammation in bronchopulmonary dysplasia by regulating HMGB-1\/TLR4\/p65\/NLRP3 signaling pathway. Discov Med 37:933. https:\/\/doi.org\/10.24976\/Discov.Med.202537196.83","journal-title":"Discov Med"},{"key":"7366_CR86","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s40001-024-01874-9","volume":"29","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Ren X, Zhang L et al (2024) Hydrogen gas inhalation ameliorates LPS-induced BPD by inhibiting inflammation via regulating the TLR4\u2013NF\u03baB\u2013IL6\/NLRP3 signaling pathway in the placenta. Eur J Med Res 29:285. https:\/\/doi.org\/10.1186\/s40001-024-01874-9","journal-title":"Eur J Med Res"},{"key":"7366_CR87","doi-asserted-by":"publisher","first-page":"79","DOI":"10.5603\/fhc.105218","volume":"63","author":"R Hao","year":"2025","unstructured":"Hao R, Li Y, Li J et al (2025) Nintedanib alleviates hyperoxia-induced lung injury via targeting NF-\u03baB signalling pathway in rat model of bronchopulmonary dysplasia. Folia Histochem Cytobiol 63:79\u201387. https:\/\/doi.org\/10.5603\/fhc.105218","journal-title":"Folia Histochem Cytobiol"},{"key":"7366_CR88","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41390-023-02643-w","volume":"94","author":"M Aslan","year":"2023","unstructured":"Aslan M, Gokce IK, Turgut H et al (2023) Molsidomine decreases hyperoxia-induced lung injury in neonatal rats. Pediatr Res 94:1341\u20131348. https:\/\/doi.org\/10.1038\/s41390-023-02643-w","journal-title":"Pediatr Res"},{"key":"7366_CR89","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s10753-021-01591-z","volume":"45","author":"J Deng","year":"2022","unstructured":"Deng J, Wang S-H, Zheng X-M, Tang Z-M (2022) Calcitonin gene-related peptide attenuates hyperoxia-induced oxidative damage in alveolar epithelial type II cells through regulating viability and transdifferentiation. Inflammation 45:863\u2013875. https:\/\/doi.org\/10.1007\/s10753-021-01591-z","journal-title":"Inflammation"},{"key":"7366_CR90","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1177\/1535370220963789","volume":"246","author":"G Guzm\u00e1n-Navarro","year":"2021","unstructured":"Guzm\u00e1n-Navarro G, de Le\u00f3n MB, Mart\u00edn-Estal I et al (2021) Prenatal indole-3-carbinol administration activates aryl hydrocarbon receptor-responsive genes and attenuates lung injury in a bronchopulmonary dysplasia model. Exp Biol Med (Maywood) 246:695\u2013706. https:\/\/doi.org\/10.1177\/1535370220963789","journal-title":"Exp Biol Med (Maywood)"},{"key":"7366_CR91","doi-asserted-by":"publisher","first-page":"C1057","DOI":"10.1152\/ajpcell.00102.2026","volume":"330","author":"HD Montgomery","year":"2026","unstructured":"Montgomery HD, Zhang MA, Zimmerman E, Helms MN (2026) Flavin adenine dinucleotide increases antioxidant availability and protects neonatal C57Bl6 lungs from high oxygen induced lung injury. Am J Physiol Cell Physiol 330:C1057\u2013C1066. https:\/\/doi.org\/10.1152\/ajpcell.00102.2026","journal-title":"Am J Physiol Cell Physiol"},{"key":"7366_CR92","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1111\/bph.70333","volume":"183","author":"A Pini","year":"2026","unstructured":"Pini A, Nardini P, Zizi V et al (2026) \u03b2(3)-adrenoceptor agonism exerts lung protection in a rat model of bronchopulmonary dysplasia. Br J Pharmacol 183:2497\u20132517. https:\/\/doi.org\/10.1111\/bph.70333","journal-title":"Br J Pharmacol"},{"key":"7366_CR93","doi-asserted-by":"publisher","first-page":"239","DOI":"10.33549\/physiolres.935239","volume":"73","author":"R Re\u00e7ica","year":"2024","unstructured":"Re\u00e7ica R, Kryeziu I, Tha\u00e7i Q et al (2024) Protective effects of resveratrol against airway hyperreactivity, oxidative stress, and lung inflammation in a rat pup model of bronchopulmonary dysplasia. Physiol Res 73:239\u2013251. https:\/\/doi.org\/10.33549\/physiolres.935239","journal-title":"Physiol Res"},{"key":"7366_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2023.171109","volume":"170","author":"Z-W Zhao","year":"2023","unstructured":"Zhao Z-W, Lin X-X, Guo Y-Z et al (2023) Irisin alleviates hyperoxia-induced bronchopulmonary dysplasia through activation of Nrf2\/HO-1 pathway. Peptides 170:171109. https:\/\/doi.org\/10.1016\/j.peptides.2023.171109","journal-title":"Peptides"},{"key":"7366_CR95","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1080\/15513815.2023.2223722","volume":"42","author":"X Chu","year":"2023","unstructured":"Chu X, Zhang X, Weng B et al (2023) Erythromycin attenuates hyperoxia induced lung injury by enhancing GSH expression and inhibiting expression of inflammatory cytokines. Fetal Pediatr Pathol 42:766\u2013774. https:\/\/doi.org\/10.1080\/15513815.2023.2223722","journal-title":"Fetal Pediatr Pathol"},{"key":"7366_CR96","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/ppul.25707","volume":"57","author":"R Ozdemir","year":"2022","unstructured":"Ozdemir R, Gokce IK, Tekin S et al (2022) The protective effects of apocynin in hyperoxic lung injury in neonatal rats. Pediatr Pulmonol 57:109\u2013121. https:\/\/doi.org\/10.1002\/ppul.25707","journal-title":"Pediatr Pulmonol"},{"key":"7366_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2023.156239","volume":"169","author":"X Yang","year":"2023","unstructured":"Yang X, Jin Z, Wang X et al (2023) Nesfatin-1 alleviates hyperoxia-induced lung injury in newborn mice by inhibiting oxidative stress through regulating SIRT1\/PGC-1\u03b1 pathway. Cytokine 169:156239. https:\/\/doi.org\/10.1016\/j.cyto.2023.156239","journal-title":"Cytokine"},{"key":"7366_CR98","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-022-02135-1","volume":"23","author":"JL Chang","year":"2022","unstructured":"Chang JL, Gong J, Rizal S et al (2022) Upregulating carnitine palmitoyltransferase 1 attenuates hyperoxia-induced endothelial cell dysfunction and persistent lung injury. Respir Res 23:205. https:\/\/doi.org\/10.1186\/s12931-022-02135-1","journal-title":"Respir Res"},{"key":"7366_CR99","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1038\/s41390-024-03562-0","volume":"97","author":"KL Ding","year":"2025","unstructured":"Ding KL, Smith C, Seedorf G, Abman SH (2025) Nintedanib preserves lung growth and prevents pulmonary hypertension in a hyperoxia-induced lung injury model. Pediatr Res 97:1676\u20131683. https:\/\/doi.org\/10.1038\/s41390-024-03562-0","journal-title":"Pediatr Res"},{"key":"7366_CR100","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.pedneo.2021.03.012","volume":"62","author":"L-T Huang","year":"2021","unstructured":"Huang L-T, Chou H-C, Chen C-M (2021) Roxadustat attenuates hyperoxia-induced lung injury by upregulating proangiogenic factors in newborn mice. Pediatr Neonatol 62:369\u2013378. https:\/\/doi.org\/10.1016\/j.pedneo.2021.03.012","journal-title":"Pediatr Neonatol"},{"key":"7366_CR101","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/iub.2588","volume":"74","author":"X Xiang","year":"2022","unstructured":"Xiang X, Zhou L, Lin Z et al (2022) Metformin regulates macrophage polarization via the Shh signaling pathway to improve pulmonary vascular development in bronchopulmonary dysplasia. IUBMB Life 74:259\u2013271. https:\/\/doi.org\/10.1002\/iub.2588","journal-title":"IUBMB Life"},{"key":"7366_CR102","doi-asserted-by":"publisher","first-page":"L586","DOI":"10.1152\/ajplung.00324.2024","volume":"328","author":"KL Daniel","year":"2025","unstructured":"Daniel KL, Gaudet C, Hamraghani A et al (2025) Sodium nitrite prevents impaired postnatal alveolar development. Am J Physiol Lung Cell Mol Physiol 328:L586\u2013L602. https:\/\/doi.org\/10.1152\/ajplung.00324.2024","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"7366_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101783","volume":"38","author":"SS Sugar","year":"2021","unstructured":"Sugar SS, Heyob KM, Cheng X et al (2021) Perinatal inflammation alters histone 3 and histone 4 methylation patterns: effects of MiR-29b supplementation. Redox Biol 38:101783. https:\/\/doi.org\/10.1016\/j.redox.2020.101783","journal-title":"Redox Biol"},{"key":"7366_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2020.104575","volume":"118","author":"L Ji","year":"2021","unstructured":"Ji L, Liu Z, Dong C et al (2021) LncRNA CASC2 targets CAV1 by competitively binding with microRNA-194-5p to inhibit neonatal lung injury. Exp Mol Pathol 118:104575. https:\/\/doi.org\/10.1016\/j.yexmp.2020.104575","journal-title":"Exp Mol Pathol"},{"key":"7366_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.resp.2023.104060","volume":"313","author":"KM Heyob","year":"2023","unstructured":"Heyob KM, Khuhro Z, Khan AQ et al (2023) Effects of DNA methylase inhibitors in a murine model of severe BPD. Respir Physiol Neurobiol 313:104060. https:\/\/doi.org\/10.1016\/j.resp.2023.104060","journal-title":"Respir Physiol Neurobiol"},{"key":"7366_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2025.117624","volume":"506","author":"H Song","year":"2026","unstructured":"Song H, Hao Q, Li J et al (2026) Overexpression of peroxiredoxin 6 in bone marrow-derived mesenchymal stem cells amplifies their in vivo effect on bronchopulmonary dysplasia by increasing mesencephalic astrocyte-derived neurotrophic factor secretion. Toxicol Appl Pharmacol 506:117624. https:\/\/doi.org\/10.1016\/j.taap.2025.117624","journal-title":"Toxicol Appl Pharmacol"},{"key":"7366_CR107","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/s41390-020-0891-9","volume":"89","author":"S Chaubey","year":"2021","unstructured":"Chaubey S, Nader YM, Shah D et al (2021) \u03b11,3-Fucosyltransferase-IX, an enzyme of pulmonary endogenous lung stem cell marker SSEA-1, alleviates experimental bronchopulmonary dysplasia. Pediatr Res 89:1126\u20131135. https:\/\/doi.org\/10.1038\/s41390-020-0891-9","journal-title":"Pediatr Res"},{"key":"7366_CR108","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl8574","volume":"14","author":"A Toth","year":"2022","unstructured":"Toth A, Steinmeyer S, Kannan P et al (2022) Inflammatory blockade prevents injury to the developing pulmonary gas exchange surface in preterm primates. Sci Transl Med 14:eabl8574. https:\/\/doi.org\/10.1126\/scitranslmed.abl8574","journal-title":"Sci Transl Med"},{"key":"7366_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2025.103285","volume":"99","author":"Q Xu","year":"2026","unstructured":"Xu Q, Li P, Gao J, Wang W (2026) Therapeutic targeting of oxidative-inflammatory crosstalk by apelin-12 in neonatal hyperoxia-induced lung injury. Tissue Cell 99:103285. https:\/\/doi.org\/10.1016\/j.tice.2025.103285","journal-title":"Tissue Cell"},{"key":"7366_CR110","doi-asserted-by":"publisher","unstructured":"Graumuller F, Rajendran DT, Li Y et al (2026) Attenuation of experimental bronchopulmonary dysplasia by dimethyl fumarate. Pediatr Res. https:\/\/doi.org\/10.1038\/s41390-026-05039-8","DOI":"10.1038\/s41390-026-05039-8"},{"key":"7366_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108190","volume":"101","author":"C Tayman","year":"2021","unstructured":"Tayman C, \u00c7ak\u0131r U, Akduman H et al (2021) The therapeutic effect of apocynin against hyperoxy and inflammation-induced lung injury. Int Immunopharmacol 101:108190. https:\/\/doi.org\/10.1016\/j.intimp.2021.108190","journal-title":"Int Immunopharmacol"},{"key":"7366_CR112","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168547","volume":"22","author":"P Das","year":"2021","unstructured":"Das P, Acharya S, Prahaladan VM et al (2021) Chitin-derived AVR-48 prevents experimental bronchopulmonary dysplasia (BPD) and BPD-associated pulmonary hypertension in newborn mice. Int J Mol Sci 22:8547. https:\/\/doi.org\/10.3390\/ijms22168547","journal-title":"Int J Mol Sci"},{"key":"7366_CR113","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1165\/rcmb.2022-0282OC","volume":"68","author":"S Soni","year":"2023","unstructured":"Soni S, Jiang Y, Zhang L et al (2023) AMPK-driven macrophage responses are autophagy dependent in experimental bronchopulmonary dysplasia. Am J Respir Cell Mol Biol 68:279\u2013287. https:\/\/doi.org\/10.1165\/rcmb.2022-0282OC","journal-title":"Am J Respir Cell Mol Biol"},{"key":"7366_CR114","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1152\/japplphysiol.00311.2024","volume":"137","author":"T Sudhadevi","year":"2024","unstructured":"Sudhadevi T, Annadi A, Basa P et al (2024) Fingolimod, a sphingosine-1-phosphate receptor modulator, prevents neonatal bronchopulmonary dysplasia and subsequent airway remodeling in a murine model. J Appl Physiol (1985) 137:1231\u20131242. https:\/\/doi.org\/10.1152\/japplphysiol.00311.2024","journal-title":"J Appl Physiol (1985)"},{"key":"7366_CR115","doi-asserted-by":"publisher","first-page":"L204","DOI":"10.1152\/ajplung.00158.2021","volume":"322","author":"Y Zhong","year":"2022","unstructured":"Zhong Y, Mahoney RC, Khatun Z et al (2022) Lysyl oxidase regulation and protein aldehydes in the injured newborn lung. Am J Physiol Lung Cell Mol Physiol 322:L204\u2013L223. https:\/\/doi.org\/10.1152\/ajplung.00158.2021","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"7366_CR116","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41390-024-03381-3","volume":"97","author":"Z Yang","year":"2025","unstructured":"Yang Z, Song J, Guo J et al (2025) Effects of PGE1 on the ERS pathway in neonatal rats with hyperoxic lung injury. Pediatr Res 97:835\u2013842. https:\/\/doi.org\/10.1038\/s41390-024-03381-3","journal-title":"Pediatr Res"},{"key":"7366_CR117","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s13105-023-00961-5","volume":"79","author":"S Zhang","year":"2023","unstructured":"Zhang S, Li X, Yuan T et al (2023) Glutamine inhibits inflammation, oxidative stress, and apoptosis and ameliorates hyperoxic lung injury. J Physiol Biochem 79:613\u2013623. https:\/\/doi.org\/10.1007\/s13105-023-00961-5","journal-title":"J Physiol Biochem"},{"key":"7366_CR118","doi-asserted-by":"publisher","first-page":"8","DOI":"10.15586\/aei.v49i6.478","volume":"49","author":"Z Liang","year":"2021","unstructured":"Liang Z, Zhang X, Liu Y et al (2021) SEMA3A protects against hyperoxia-induced lung injury in a bronchopulmonary dysplasia model of newborn rat by inhibiting ERK pathway. Allergol Immunopathol (Madr) 49:8\u201315. https:\/\/doi.org\/10.15586\/aei.v49i6.478","journal-title":"Allergol Immunopathol (Madr)"},{"key":"7366_CR119","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0285944","volume":"18","author":"C-H Lee","year":"2023","unstructured":"Lee C-H, Su T-C, Lee M-S et al (2023) Heat shock protein 70 protects the lungs from hyperoxic injury in a neonatal rat model of bronchopulmonary dysplasia. PLoS ONE 18:e0285944. https:\/\/doi.org\/10.1371\/journal.pone.0285944","journal-title":"PLoS ONE"},{"key":"7366_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-94794-5","volume":"15","author":"A Xie","year":"2025","unstructured":"Xie A, Qian W, Ye D et al (2025) Sodium propionate protects against bronchopulmonary dysplasia by inhibiting IL-17-mediated apoptosis of alveolar epithelial cells. Sci Rep 15:11722. https:\/\/doi.org\/10.1038\/s41598-025-94794-5","journal-title":"Sci Rep"},{"key":"7366_CR121","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1177\/15353702231199468","volume":"248","author":"I Kryeziu","year":"2023","unstructured":"Kryeziu I, Re\u00e7ica S, Tha\u00e7i Q et al (2023) Quercetin supplementation attenuates airway hyperreactivity and restores airway relaxation in rat pups exposed to hyperoxia. Exp Biol Med (Maywood) 248:1492\u20131499. https:\/\/doi.org\/10.1177\/15353702231199468","journal-title":"Exp Biol Med (Maywood)"},{"key":"7366_CR122","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.70728","volume":"14","author":"RB Sopi","year":"2026","unstructured":"Sopi RB, Tha\u00e7i Q, Raffay TM, Beqiraj-Zeqiraj Q (2026) Inhibition of Rho-kinase restores impaired relaxation of airway smooth muscle in rat pups exposed to neonatal hyperoxia. Physiol Rep 14:e70728. https:\/\/doi.org\/10.14814\/phy2.70728","journal-title":"Physiol Rep"},{"key":"7366_CR123","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12929-023-00958-8","volume":"30","author":"C-M Chen","year":"2023","unstructured":"Chen C-M, Yang Y-CSH, Chou H-C, Lin S (2023) Intranasal administration of Lactobacillus johnsonii attenuates hyperoxia-induced lung injury by modulating gut microbiota in neonatal mice. J Biomed Sci 30:57. https:\/\/doi.org\/10.1186\/s12929-023-00958-8","journal-title":"J Biomed Sci"},{"key":"7366_CR124","doi-asserted-by":"publisher","DOI":"10.1155\/mi\/4965271","author":"M Zhang","year":"2024","unstructured":"Zhang M, Li D, Sun L et al (2024) Lactobacillus reuteri alleviates hyperoxia-induced BPD by activating IL-22\/STAT3 signaling pathway in neonatal mice. Mediators Inflamm. https:\/\/doi.org\/10.1155\/mi\/4965271","journal-title":"Mediators Inflamm"},{"key":"7366_CR125","doi-asserted-by":"publisher","first-page":"L545","DOI":"10.1152\/ajplung.00195.2021","volume":"321","author":"C Guillier","year":"2021","unstructured":"Guillier C, Carri\u00e8re D, Pansiot J et al (2021) Nebulized curcumin protects neonatal lungs from antenatal insult in rats. Am J Physiol Lung Cell Mol Physiol 321:L545\u2013L552. https:\/\/doi.org\/10.1152\/ajplung.00195.2021","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"7366_CR126","first-page":"8","volume":"30","author":"AN Massaro","year":"2025","unstructured":"Massaro AN, Fletcher EP, Madabushi R et al (2025) A pediatric research imperative: addressing neonates in drug development through understanding neonatal clinical pharmacology. J Pediatr Pharmacol Ther 30:8\u201316","journal-title":"J Pediatr Pharmacol Ther"},{"key":"7366_CR127","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.2174\/1381612821666150901105146","volume":"21","author":"M Roth-Cline","year":"2015","unstructured":"Roth-Cline M, Nelson R (2015) Ethical considerations in conducting pediatric and neonatal research in clinical pharmacology. Curr Pharm Des 21:5619\u20135635","journal-title":"Curr Pharm Des"},{"key":"7366_CR128","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2352-4642(25)00106-3","volume":"9","author":"D De Luca","year":"2025","unstructured":"De Luca D, Modi N, Davis P et al (2025) The Lancet Child & adolescent health commission on the future of neonatology. Lancet Child Adolesc Health 9:578\u2013612. https:\/\/doi.org\/10.1016\/S2352-4642(25)00106-3","journal-title":"Lancet Child Adolesc Health"},{"key":"7366_CR129","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (2026) Global strategy for prevention, diagnosis and management of COPD: 2026 report. https:\/\/goldcopd.org\/2026-gold-report-and-pocket-guide\/. Accessed 16 August 2026"},{"key":"7366_CR130","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s00431-017-3009-6","volume":"176","author":"M \u00c1lvarez-Fuente","year":"2017","unstructured":"\u00c1lvarez-Fuente M, Arruza L, Muro M et al (2017) The economic impact of prematurity and bronchopulmonary dysplasia. Eur J Pediatr 176:1587\u20131593","journal-title":"Eur J Pediatr"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-07366-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-026-07366-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-07366-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:02:50Z","timestamp":1789225370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-026-07366-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,5]]},"references-count":130,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["7366"],"URL":"https:\/\/doi.org\/10.1007\/s00431-026-07366-8","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,5]]},"assertion":[{"value":"2 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NA.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EB and LB declare that they acted as external experts for ExoBiologics and Oak Hill Bio. DDL received speaker or consulting fee or research assistance from Airway Therapeutics, Oak Hill Bio, Chiesi Farmaceutici, Medtronic, Getinge, Zoll, Radiometer, Mediprema. VN is an employee and shareholder in Oak Hill Bio Holdings (previously known as Oak Hill Bio Ltd). LZ, SS, EV, DN, EP, declare no conflicts of interest.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"721"}}